SPARTAN Group

Spondyloarthritis Research and Treatment Network

  • Become a SPARTAN Member
  • Donate
  • Contact Us
  • Log In
  • Home
  • About Us
    • About Spondyloarthritis
    • About SPARTAN
    • Corporate Supporters
    • Leadership
    • Committees
    • Awards
    • The Latest News from SPARTAN
    • Bylaws
  • Membership
    • Become a SPARTAN Member
    • Member Directory
  • Annual Meeting
    • 2025 Annual Meeting Toronto
    • 2025 Annual Meeting Agenda
    • 2025 Spondyloarthritis Review Course
    • Trainee Abstracts
    • Information for Sponsors
    • Past Conference Materials
  • Projects
    • SPARTAN Projects
    • CLASSIC Study
  • Grants
    • Spondyloarthritis Fellowship Training Award
      • Award Information
      • Past Awardees
    • Early Career Investigator Award
      • Award Information
      • Past Awardees
    • Mentored Fellowship Award
      • Award Information
      • Past Awardees
    • Spondyloarthritis Research Fellowship
      • Award Information
      • Past Awardees
    • SPARTAN Overhead Policy
  • Education
    • SPARTAN-PANLAR axSpA Pre-congress Educational Course
    • SPARTAN GRAPPA ASAS Symposium
    • CAPES Education Series
    • GRAPPA SPARTAN Global Education Seminars
    • Case Library
    • Treatment Guidelines
  • Members
    • Password Reset
    • Log Out

ACR-SPARTAN-SAA AxSpA Guidelines

Rheumatology and Spondylitis Organizations Release Updated Treatment Guideline for Axial Spondyloarthritis

On August 22, 2019, the American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA). The guideline includes 86 recommendations that provide updated and new guidance for the management of patients with AS and nr-axSpA in the areas of pharmacologic and non-pharmacologic treatment options; AS-related comorbidities; and disease activity assessment, imaging, and screening.

“These guidelines update those from four years ago by consolidating the expert thought around the use of the newest therapeutic agents and modifying a number of recommendations from the 2015 guideline to reflect recent evidence. They provide patients and the medical community with clear recommendations for spondyloarthritis management using a rigorous approach, and SPARTAN is proud to endorse them,” said Dr. Liron Caplan, chair of SPARTAN.

“SAA is proud to be a co-sponsor of these updated guidelines. SAA is committed to expanding treatment options and ensuring that both spondyloarthritis patients and the medical practitioners that are entrusted with their care have the best resources to aid in their decision-making,” said Cassie Shafer, chief executive officer of the SAA.

The ACR’s previous guideline, published in 2015, provided recommendations for pharmacological treatments, management of selected comorbidities, disease monitoring, and preventive care. The 2019 update builds on these recommendations by adding information on new medications, managing biologic and biosimilars usage in patients, and best practices for utilizing imaging (MRI and radiographs).

“Based on the literature, we felt it was important to address topics such as sequencing biologics for patients with active AS despite NSAID usage, whether to taper or discontinue biologics in the setting of remission, and clearer guidelines on when to obtain images – particularly in instances when results would likely lead to a change in treatment,” said Michael Ward, MD, MPH, researcher at the National Institute of Arthritis and Musculoskeletal and Skin Diseases and principal investigator of the guideline. “We hope this new information will help get patients on an effective treatment faster and ultimately improve patients’ health status and quality of life.”

The updated and expanded recommendations, supporting PICO questions and evidence report are available in report below…

2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA)

 

About US

About SPARTAN
Leadership
Committees
ByLaws

Keep in Touch with SPARTAN

Receive the SPARTAN email newsletter, published quarterly.

Browse newsletter archives.

Twitter @spartan_updates
SPARTAN on LinkedIn

Contact Us

SPARTAN Office
PO Box 55491
Portland, OR 97238

Copyright © 2025 SPARTAN · Log in